Kelsey Klute

3.1k total citations
26 papers, 348 citations indexed

About

Kelsey Klute is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kelsey Klute has authored 26 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Kelsey Klute's work include Cancer Genomics and Diagnostics (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Kelsey Klute is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Kelsey Klute collaborates with scholars based in United States, United Kingdom and Canada. Kelsey Klute's co-authors include Shinsuke Tasaki, Eleni Nackos, Daniel P. Nguyen, Neil H. Bander, Scott T. Tagawa, E Popa, Allyson J. Ocean, Manish A. Shah, Paul J. Christos and Carolyn D. Runowicz and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cell and Cancer Research.

In The Last Decade

Kelsey Klute

24 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kelsey Klute United States	8	166	128	64	56	52	26	348
Carolina Ortiz Spain	9	218 1.3×	158 1.2×	74 1.2×	88 1.6×	45 0.9×	27	433
Séverine Sarp Switzerland	9	196 1.2×	119 0.9×	76 1.2×	109 1.9×	26 0.5×	18	398
Ken Saijo Japan	12	232 1.4×	203 1.6×	133 2.1×	52 0.9×	34 0.7×	47	530
Rabih Said United States	11	153 0.9×	118 0.9×	105 1.6×	118 2.1×	29 0.6×	33	390
Päivi Sirniö Finland	10	206 1.2×	128 1.0×	63 1.0×	120 2.1×	41 0.8×	17	378
Nathan D. Seligson United States	13	213 1.3×	192 1.5×	165 2.6×	108 1.9×	29 0.6×	38	532
Sara A. Väyrynen Finland	11	233 1.4×	93 0.7×	56 0.9×	62 1.1×	23 0.4×	17	408
József Lövey Hungary	12	168 1.0×	90 0.7×	153 2.4×	49 0.9×	21 0.4×	46	406
Lígia Traldi Macedo Brazil	12	298 1.8×	71 0.6×	174 2.7×	65 1.2×	76 1.5×	29	499
Yingyi Zhang China	10	114 0.7×	117 0.9×	155 2.4×	45 0.8×	27 0.5×	21	448

Countries citing papers authored by Kelsey Klute

Since Specialization

Citations

This map shows the geographic impact of Kelsey Klute's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelsey Klute with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelsey Klute more than expected).

Fields of papers citing papers by Kelsey Klute

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelsey Klute. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelsey Klute. The network helps show where Kelsey Klute may publish in the future.

Co-authorship network of co-authors of Kelsey Klute

This figure shows the co-authorship network connecting the top 25 collaborators of Kelsey Klute. A scholar is included among the top collaborators of Kelsey Klute based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelsey Klute. Kelsey Klute is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hosein, Peter J., Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2025). Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 43(4_suppl). 715–715. 1 indexed citations

Triplett, Aleata A., Vijender Chaitankar, Quan P. Ly, et al.. (2024). Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals. Cancer Letters. 607. 217321–217321. 3 indexed citations

Klute, Kelsey, et al.. (2024). Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies. Cancers. 16(13). 2432–2432. 9 indexed citations

Klute, Kelsey, Vincent J. Picozzi, Nashat Gabrail, et al.. (2024). Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4214–TPS4214. 2 indexed citations

Klute, Kelsey, Soonjo Hwang, Yeongjin Gwon, et al.. (2024). Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma. Cancer Research. 84(2_Supplement). C001–C001. 2 indexed citations

Cannon, Timothy Lewis, Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2023). Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(4_suppl). 546–546. 2 indexed citations

Zhang, Chunmeng, et al.. (2023). Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review. Annals of Surgical Oncology. 31(2). 792–803. 2 indexed citations

Klute, Kelsey, Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2022). Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer WithBRAFMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 6(6). e2200191–e2200191. 16 indexed citations

Navari, Rudolph M., G. Binder, Alex Molassiotis, et al.. (2022). Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. The Oncologist. 28(3). 208–213. 7 indexed citations

10.

He, Dan, Huijin Feng, Belen Sundberg, et al.. (2022). Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. Molecular Cell. 82(16). 3045–3060.e11. 47 indexed citations

11.

Zogopoulos, George, Yan Bi, Randall E. Brand, et al.. (2022). The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.. Journal of Clinical Oncology. 40(16_suppl). e16239–e16239.

12.

Winfree, Seth, Heather Jensen‐Smith, Benjamin Swanson, et al.. (2022). Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors1. Cancer Biomarkers. 33(2). 219–235. 6 indexed citations

13.

Spencer, Kristen, Anita Turk, Shikha Jain, et al.. (2022). BTCRC-GI20-457: A phase II study of atezolizumab and bevacizumab in Child-Pugh B7 hepatocellular carcinoma (the AB7 Trial).. Journal of Clinical Oncology. 40(4_suppl). TPS493–TPS493. 1 indexed citations

14.

Griggs, Jennifer J., Kari Bohlke, Edward P. Balaban, et al.. (2021). Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 39(18). 2037–2048. 75 indexed citations

15.

Lin, Chi, Jean L. Grem, Kelsey Klute, et al.. (2021). The Phase I Results of a Phase 1/2 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5-Fluorouracil, Mitomycin and BMX-001. International Journal of Radiation Oncology*Biology*Physics. 111(3). S103–S103. 1 indexed citations

16.

Reames, Bradley N., Kelsey Klute, William A. Hall, et al.. (2021). The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?. Clinical and Translational Radiation Oncology. 28. 124–128. 6 indexed citations

17.

Schneider, Bryan J., Manish A. Shah, Kelsey Klute, et al.. (2016). Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. Clinical Cancer Research. 23(11). 2673–2680. 51 indexed citations

18.

Klute, Kelsey, Minaxi Jhawer, Allyson J. Ocean, et al.. (2016). Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis. European Journal of Cancer. 63. 189–200. 43 indexed citations

19.

Klute, Kelsey, et al.. (2016). Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience. Journal of Thrombosis and Thrombolysis. 42(2). 267–271. 7 indexed citations

20.

Tagawa, Scott T., Kelsey Klute, Eleni Nackos, et al.. (2014). Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy. 7. 2227–2227. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact